Project Grant R01CA309759
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $434K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27708, USA
Similar Awards
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate tumor regenerative cell populations and develop L1CAM-targeted antibody-drug conjugates that may overcome resistance to neoadjuvant therapy in locally advanced rectal cancer. The project will use genomic and transcriptomic analysis of pre-treatment rectal tumors, mechanistic studies in patient-derived organoid...
- The National Cancer Institute awarded Duke University $395,846 on April 1, 2026, as a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to support research on therapeutic targeting of SMARCAL1 in therapy-resistant gliomas through May 31, 2031. The research addresses alternative lengthening of telomeres (ALT), a telomerase-independent mechanism through which 10–15% of cancers achieve replicative immortality. IDH-mutant astrocytomas, characterized by co-occurring mutations in...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $402,011 to The University of Texas Southwestern Medical Center on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how the KEAP1-NRF2 redox-sensing pathway regulates CD8 T-cell adaptation to persistent antigen receptor signaling in cancer and chronic infection contexts. The funded research addresses T-cell exhaustion, a dysfunctional...
- The National Cancer Institute, part of the National Institutes of Health under the Department of Health and Human Services, awarded Duke University $302,524 on September 10, 2025, under the Cancer Research Manpower program (CFDA 93.398). The award funds a postdoctoral research fellowship (F32) to investigate the role of SMARCAL1, an annealing helicase, in promoting glioma cell proliferation and suppressing tumor-intrinsic inflammation in alternative lengthening of telomeres (ALT)–positive...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $452,540 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the innate and adaptive immune determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T cell therapy. CRS occurs in approximately 93 percent of patients receiving CAR T cell therapy, manifesting as fever, hypotension, hypoxia, and dyspnea due to rapid increases in multiple cytokines...
- The National Cancer Institute awarded the University of Texas Health Science Center at Houston $663,818 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to assess the impact of early physiotherapy on lymphatic dysfunction in breast cancer survivorship through longitudinal measurement of lymphatic dysfunction using quantitative near-infrared fluorescence lymphatic imaging, evaluation of early physical rehabilitation with advanced pneumatic compression on lymphatic...
- The National Cancer Institute awarded $624,194 to the University of North Carolina at Chapel Hill on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how the integrated stress response regulates CD8+ tumor-infiltrating lymphocyte metabolic function in hypoxic tumor microenvironments and its role in immunotherapy resistance. The project addresses metabolic stress as a barrier to CD8+ T cell antitumor function in solid cancers, with focus on activating...